Abstract:Abstract Background Molecular and cytogenetic abnormalities characterize the biologic heterogeneity of B-ALL and provide a strong and independent prognostic factor for treatment outcome. Emerging data highlight the role of tyrosine kinase inhibition (TKI) in those with Philadelphia chromosome positive (Ph+) B-ALL. A new high risk subset, so-called Ph-like ALL, has been recognized, comprising 10-15% of pediatric B-ALL. These cases show similar alterations in IKZF1, and are likely driven by alternative kinase rearrangements, including CRLF2, JAK2, ABL1, and others. Increased STAT5 phosphorylation may broadly classify such patients, and, also suggest a benefit with JAK2 inhibitors or TKI’s. Finally, c-MYC has been recognized as a high risk feature for both B- and T-ALL, though it is unclear whether the risk is similar among Ph+ and Ph- patients in the era of TKI-based therapy. Method and Materials A retrospective analysis was performed of a series of patients at Moffitt Cancer Center with B-ALL diagnosed between January 2003 and June 2012. Of them, paraffin embedded blocks from patients who had the first diagnostic bone marrow biopsy performed at MCC with a good biopsy quality (> 1.0 cm in length and tumor load over 70% of marrow cellularity) were selected for performing immunohistochemical (IHC) study. Ten normal bone marrows were also included as antibody base-line control. IHC stains were performed according to institutional standard protocol and modified based on the individually purchased antibody. Expression of pSTAT5, c-MYC, and IKZF1 on lymphoblasts was assessed semiquantitatively based on the expression score calculated with staining strength and multiplied by percentage positivity on tumor cells. Clinical outcomes were correlated to the IHC scores. Hazard ratios were generated using standard cox regression analysis. Patient survival was analyzed with Kaplan-Meier method from the date of diagnosis until death from any cause. Results 29 B-ALL patients, including 15 Ph+ and 14 Ph-, with median age 58years (19 - 72), median white blood cells (WBC) 10.1 k/uL (1.8-200), and male to female ratio of 2:1, were included in the study. 86% received HyperCVAD induction, and 93% of Ph+ patients received TKI therapy, most commonly with Imatinib (86%), and 32% received an allogeneic transplant in first remission. No significant difference in age, WBC, or receipt of allogeneic transplant, time to progression (TTP), or overall survival OS was apparent when comparing Ph+ to Ph- patients. The IHC staining results showed nuclear expression of pSTAT5 to be more frequently present in Ph+ B-ALL than in Ph- B-ALL (73% vs 33%, p = 0.0574), however, no differences in staining were observed with IKZF1 (80% vs 92%, p=0.61) or c-MYC (33% vs 50%, p=0.41). Overexpression of c-MYC was associated with decrease in OS (HR 4.1, 95%CI 1.2-13.9, p=0.02)(Figure 1), with a trend towards decreased TTP (HR 4.3, 95% CI 0.8-22.2, p=0.08). Neither pSTAT5 nor IKZF1 were predictive of OS or TTP when analyzing the entire cohort. Further analysis of the Ph+ group demonstrated a trend for impaired OS among c-MYC positive patients (HR 4.3, 95%CI 0.8-22.2, p=.08). There was no significant impact of c-MYC on TTP, and no impact of pSTAT5 or IKZF1 expression in regards to TTP or OS. 23% Ph+ patients and 7% Ph- patients showed loss of IKZF1 expression (p=0.61). Further analysis of the Ph- group demonstrated a trend towards impaired TTP among those with high expression of pSTAT5 (HR 9.4, 95%CI 0.8-105.8, p=0.07). There was no impact of pSTAT5 on OS, and no impact of IKZF1 or c-MYC expression in regards to TTP or OS. Conclusion Ph+ B-ALL patients more commonly expressed pSTAT5, but this did not influence outcome, perhaps due to TKI exposure. A subset of Ph- patients with high pSTAT5 had a trend towards lower OS in comparison to Ph- and pSTAT5 negative patients (figure 2). This may be a novel group for the study of TKI or JAK2 inhibitors. Expression of c-MYC was associated with impaired OS and a trend towards lower TTP, an effect which was most pronounced in the Ph+ group. Disclosures: No relevant conflicts of interest to declare.

Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity

Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia

Minimal Residual Disease-guided Risk Restratification and Therapy Improves the Survival of Childhood Acute Lymphoblastic Leukemia: Experience from a Tertiary Children's Hospital in China

Clinical and Genetic Characteristics of <i>IKZF1</i> Mutation in Chinese Children With B-Cell Acute Lymphoblastic Leukemia

Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia

[Long-Term Outcome of Childhood T-cell Acute Lymphoblastic Leukemia Treated with Modified National Protocol of Childhood Leukemia in China-acute Lymphoblastic Leukemia 2008].

Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia

[Monitoring of Minimal Residual Disease in Children with Acute Lymphoblastic Leukemia and Its Prognostic Significance].

The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis.

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia

Prognosis of pediatric BCP‐ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG‐2016 study

Minimal Residual Disease Detection by Next-Generation Sequencing of Different Immunoglobulin Gene Rearrangements in Pediatric B-ALL

Characterisation of cells markers associated with IKZF1plus in BCP-ALL

Quantitative Analysis of IKZF1 Gene Deletions in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia: Higher Levels Are Associated with a Poorer Prognosis.

IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia

CD34+CD38-CD58- Candidate Leukemia-Initiating Cells Are Clinically Relevant with the Unfavorable Prognosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre

Cd34(+)Cd38(-)Cd58(-) Leukemia-Propagating Cells At Diagnosis Could Identify Patients At High-Risk For Relapse In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China

Expression Level of P-Stat5, C-Myc and IKZF1 by Immunohistochemistry Might Correlate with Adverse Clinic Outcome in Adult B- Lymphoblastic Leukemia (B-ALL)

Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia